艾滋病毒感染者心血管风险预测模型的比较性能

IF 1.6 4区 医学 Q4 INFECTIOUS DISEASES
Irtiza S Tahir, Alinda G Vos, Johanna A A Damen, Roos E Barth, Hugo A Tempelman, Diederick E Grobbee, Karine Scheuermaier, Willem D F Venter, Kerstin Klipstein-Grobusch
{"title":"艾滋病毒感染者心血管风险预测模型的比较性能","authors":"Irtiza S Tahir,&nbsp;Alinda G Vos,&nbsp;Johanna A A Damen,&nbsp;Roos E Barth,&nbsp;Hugo A Tempelman,&nbsp;Diederick E Grobbee,&nbsp;Karine Scheuermaier,&nbsp;Willem D F Venter,&nbsp;Kerstin Klipstein-Grobusch","doi":"10.4102/sajhivmed.v23i1.1395","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Current cardiovascular risk assessment in people living with HIV is based on general risk assessment tools; however, whether these tools can be applied in sub-Saharan African populations has been questioned.</p><p><strong>Objectives: </strong>The study aimed to assess cardiovascular risk classification of common cardiovascular disease (CVD) risk prediction models compared to the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) 2010 and 2016 models in people living with HIV.</p><p><strong>Method: </strong>Cardiovascular disease risk was estimated by Framingham Cardiovascular and Heart Disease (FHS-CVD, FHS-CHD), Atherosclerotic Cardiovascular Disease (ASCVD) and D:A:D 2010 and 2016 risk prediction models for HIV-infected participants of the Ndlovu Cohort Study, Limpopo, rural South Africa. Participants were classified to be at low (< 10%), moderate (10% - 20%), or high-risk (> 20%) of CVD within 10 years for general CVD and five years for D:A:D models. Kappa statistics were used to determine agreement between CVD risk prediction models. Subgroup analysis was performed according to age.</p><p><strong>Results: </strong>The analysis comprised 735 HIV-infected individuals, predominantly women (56.7%), average age 43.9 (8.8) years. The median predicted CVD risk for D:A:D 2010 and FHS-CVD was 4% and for ASCVD and FHS-CHD models, 3%. For the D:A:D 2016 risk prediction model, the figure was 5%. High 10-year CVD risk was predicted for 2.9%, 0.5%, 0.7%, 3.1% and 6.6% of the study participants by FHS-CVD, FHS-CHD, ASCVD, and D:A:D 2010 and 2016. Kappa statistics ranged from 0.34 for ASCVD to 0.60 for FHS-CVD as compared to the D:A:D 2010 risk prediction model.</p><p><strong>Conclusion: </strong>Overall, predicted CVD risk is low in this population. Compared to D:A:D 2010, CVD risk estimated by the FHS-CVD model showed similar overall results for risk classification. With the exception of the D:A:D model, all other risk prediction models classified fewer people to be at high estimated CVD risk. Prospective studies are needed to develop and validate CVD risk algorithms in people living with HIV in sub-Saharan Africa.</p>","PeriodicalId":49489,"journal":{"name":"Southern African Journal of Hiv Medicine","volume":"23 1","pages":"1395"},"PeriodicalIF":1.6000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724117/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparative performance of cardiovascular risk prediction models in people living with HIV.\",\"authors\":\"Irtiza S Tahir,&nbsp;Alinda G Vos,&nbsp;Johanna A A Damen,&nbsp;Roos E Barth,&nbsp;Hugo A Tempelman,&nbsp;Diederick E Grobbee,&nbsp;Karine Scheuermaier,&nbsp;Willem D F Venter,&nbsp;Kerstin Klipstein-Grobusch\",\"doi\":\"10.4102/sajhivmed.v23i1.1395\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Current cardiovascular risk assessment in people living with HIV is based on general risk assessment tools; however, whether these tools can be applied in sub-Saharan African populations has been questioned.</p><p><strong>Objectives: </strong>The study aimed to assess cardiovascular risk classification of common cardiovascular disease (CVD) risk prediction models compared to the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) 2010 and 2016 models in people living with HIV.</p><p><strong>Method: </strong>Cardiovascular disease risk was estimated by Framingham Cardiovascular and Heart Disease (FHS-CVD, FHS-CHD), Atherosclerotic Cardiovascular Disease (ASCVD) and D:A:D 2010 and 2016 risk prediction models for HIV-infected participants of the Ndlovu Cohort Study, Limpopo, rural South Africa. Participants were classified to be at low (< 10%), moderate (10% - 20%), or high-risk (> 20%) of CVD within 10 years for general CVD and five years for D:A:D models. Kappa statistics were used to determine agreement between CVD risk prediction models. Subgroup analysis was performed according to age.</p><p><strong>Results: </strong>The analysis comprised 735 HIV-infected individuals, predominantly women (56.7%), average age 43.9 (8.8) years. The median predicted CVD risk for D:A:D 2010 and FHS-CVD was 4% and for ASCVD and FHS-CHD models, 3%. For the D:A:D 2016 risk prediction model, the figure was 5%. High 10-year CVD risk was predicted for 2.9%, 0.5%, 0.7%, 3.1% and 6.6% of the study participants by FHS-CVD, FHS-CHD, ASCVD, and D:A:D 2010 and 2016. Kappa statistics ranged from 0.34 for ASCVD to 0.60 for FHS-CVD as compared to the D:A:D 2010 risk prediction model.</p><p><strong>Conclusion: </strong>Overall, predicted CVD risk is low in this population. Compared to D:A:D 2010, CVD risk estimated by the FHS-CVD model showed similar overall results for risk classification. With the exception of the D:A:D model, all other risk prediction models classified fewer people to be at high estimated CVD risk. Prospective studies are needed to develop and validate CVD risk algorithms in people living with HIV in sub-Saharan Africa.</p>\",\"PeriodicalId\":49489,\"journal\":{\"name\":\"Southern African Journal of Hiv Medicine\",\"volume\":\"23 1\",\"pages\":\"1395\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724117/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Southern African Journal of Hiv Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4102/sajhivmed.v23i1.1395\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Southern African Journal of Hiv Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4102/sajhivmed.v23i1.1395","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:目前艾滋病毒感染者的心血管风险评估是基于一般风险评估工具;然而,这些工具是否适用于撒哈拉以南非洲人口一直受到质疑。目的:本研究旨在比较2010年和2016年抗HIV药物不良事件数据收集(D:A:D)模型在HIV感染者中常见心血管疾病(CVD)风险预测模型的心血管风险分类。方法:采用Framingham Cardiovascular and Heart disease (FHS-CVD)、FHS-CHD、动脉粥样硬化性心血管疾病(ASCVD)和D:A:D 2010年和2016年风险预测模型对南非农村林波波省Ndlovu队列研究的hiv感染者进行心血管疾病风险评估。一般CVD患者在10年内分为低(< 10%)、中度(10% - 20%)或高危(> 20%),D:A:D患者在5年内分为高危(> 20%)。采用Kappa统计来确定CVD风险预测模型之间的一致性。按年龄进行亚组分析。结果:该分析包括735名艾滋病毒感染者,主要是女性(56.7%),平均年龄43.9(8.8)岁。D:A:D 2010和FHS-CVD模型的中位预测心血管疾病风险为4%,ASCVD和FHS-CHD模型的中位预测风险为3%。对于D:A:D 2016年风险预测模型,这一数字为5%。2010年和2016年,FHS-CVD、FHS-CHD、ASCVD和D:A:D预测的10年心血管疾病高风险分别为2.9%、0.5%、0.7%、3.1%和6.6%。与D:A:D 2010风险预测模型相比,ASCVD的Kappa统计值为0.34,FHS-CVD的Kappa统计值为0.60。结论:总体而言,该人群预测的心血管疾病风险较低。与D:A:D 2010相比,FHS-CVD模型估计的CVD风险在风险分类方面显示出相似的总体结果。除D:A:D模型外,所有其他风险预测模型都将较少的人归为CVD高估计风险。需要进行前瞻性研究,以开发和验证撒哈拉以南非洲艾滋病毒感染者的心血管疾病风险算法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Comparative performance of cardiovascular risk prediction models in people living with HIV.

Comparative performance of cardiovascular risk prediction models in people living with HIV.

Comparative performance of cardiovascular risk prediction models in people living with HIV.

Comparative performance of cardiovascular risk prediction models in people living with HIV.

Background: Current cardiovascular risk assessment in people living with HIV is based on general risk assessment tools; however, whether these tools can be applied in sub-Saharan African populations has been questioned.

Objectives: The study aimed to assess cardiovascular risk classification of common cardiovascular disease (CVD) risk prediction models compared to the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) 2010 and 2016 models in people living with HIV.

Method: Cardiovascular disease risk was estimated by Framingham Cardiovascular and Heart Disease (FHS-CVD, FHS-CHD), Atherosclerotic Cardiovascular Disease (ASCVD) and D:A:D 2010 and 2016 risk prediction models for HIV-infected participants of the Ndlovu Cohort Study, Limpopo, rural South Africa. Participants were classified to be at low (< 10%), moderate (10% - 20%), or high-risk (> 20%) of CVD within 10 years for general CVD and five years for D:A:D models. Kappa statistics were used to determine agreement between CVD risk prediction models. Subgroup analysis was performed according to age.

Results: The analysis comprised 735 HIV-infected individuals, predominantly women (56.7%), average age 43.9 (8.8) years. The median predicted CVD risk for D:A:D 2010 and FHS-CVD was 4% and for ASCVD and FHS-CHD models, 3%. For the D:A:D 2016 risk prediction model, the figure was 5%. High 10-year CVD risk was predicted for 2.9%, 0.5%, 0.7%, 3.1% and 6.6% of the study participants by FHS-CVD, FHS-CHD, ASCVD, and D:A:D 2010 and 2016. Kappa statistics ranged from 0.34 for ASCVD to 0.60 for FHS-CVD as compared to the D:A:D 2010 risk prediction model.

Conclusion: Overall, predicted CVD risk is low in this population. Compared to D:A:D 2010, CVD risk estimated by the FHS-CVD model showed similar overall results for risk classification. With the exception of the D:A:D model, all other risk prediction models classified fewer people to be at high estimated CVD risk. Prospective studies are needed to develop and validate CVD risk algorithms in people living with HIV in sub-Saharan Africa.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.80
自引率
11.80%
发文量
41
审稿时长
>12 weeks
期刊介绍: The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and to support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice, and correspondence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信